Who currently manages keytruda's patents?

Who manages Keytruda patents?

Merck owns the patents covering Keytruda. Merck manages them through its own intellectual property department.

Why are companies challenging this patent?

Companies seek to design around Keytruda's patents or launch biosimilars once patents expire. Merck has faced multiple patent challenges from biosimilar developers aiming to enter the market early.

How does Keytruda compare with other checkpoint inhibitors?

Keytruda stands as the top-selling checkpoint inhibitor with broader indications than most competitors. It covers cancer types that other drugs like Opdivo or Tecentriq do not.

When does Keytruda's patent expire?

Keytruda's composition of matter patent expires in 2028. Merck holds additional patents covering formulations, methods of use, and manufacturing that can extend exclusivity past 2028.

What side effects are patients asking about?

Patients report immune-related adverse events such as colitis, hepatitis, and endocrine disorders. Merck has issued warnings about these risks along with others like infusion reactions.

Can biosimilars enter before patent expiry?

Biosimilars cannot launch legally before patents expire unless a court rules against Merck or Merck grants a license. Early entry requires winning a patent challenge or receiving a settlement agreement.

Who makes Keytruda?

Merck manufactures Keytruda itself. It keeps manufacturing in-house to control quality and keep data on manufacturing methods confidential.

When does Keytruda's exclusivity expire?

Exclusivity periods for Keytruda extend past the basic patent expiry in 2028. Merck expects regulatory exclusivity and secondary patents to block biosimilars until at least 2032.

Why is Keytruda's price so high?

Keytruda's price reflects investment in clinical trials spanning many cancer types. The company justifies the price through demonstrated survival benefits in multiple indications.